Neoadjuvant sunitinib facilitates nephron-sparing surgery and avoids long-term dialysis in a patient with metachronous contralateral renal cell carcinoma

Clinical Genitourinary Cancer

Volumn 7, Issue 2, 2009, Pages

  Ansari, Jawaher ^a   Doherty, Alan ^a   McCafferty, Ian ^a   Wallace, Michael ^a   Deshmukh, Nayneeta ^a   Porfiri, Emilio ^a  

^a UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Bilateral disease; Clear cell carinoma; Left sided radical nephrectomy; Renal cancer

Indexed keywords

SUNITINIB;

ADULT; ARTICLE; CANCER GRADING; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; GLOMERULUS FILTRATION RATE; HEMODIALYSIS; HUMAN; KIDNEY CARCINOMA; NEPHRECTOMY; NEPHRON SPARING SURGERY; TUMOR VOLUME;

EID: 70449427408     PISSN: 15587673     EISSN: None     Source Type: Journal    
DOI: 10.3816/CGC.2009.n.021     Document Type: Article

References (17)

1. Siemer S, Uder M, Zell A, et al. Bilateral kidney tumor. Therapy management and histopathological results with long-term follow-up of 66 patients. Urologe A 2001; 40:114-120
2. Grimaldi G, Reuter V, Russo P. Bilateral non-familial renal cell carcinoma. Ann Surg Oncol 1998; 5:548-552
3. Klatte T, Patard JJ, Wunderlich H, et al. Metachronous bilateral renal cell carcinoma: risk assessment, prognosis and relevance of the primary-free interval. J Urol 2007; 177:2081-2087
4. Lee CT, Katz J, Shi W, et al. Surgical management of renal tumors 4 cm or less in a contemporary cohort. J Urol 2000; 163:730-736
5. Uzzo RG, Novick AC. Nephron-sparing surgery for renal tumors: indications, techniques and outcomes. J Urol 2001; 166:6-18.
6. Coppin C, Porzsolt F, Awa A, et al. Immunotherapy for advanced renal cell cancer. Cochrane Database Syst Rev 2005; (1):CD001425.
7. Bex A, Horenblas S, Meinhardt W, et al. The role of initial immunotherapy as selection for nephrectomy in patients with metastatic renal cell carcinoma and the primary tumor in situ. Eur Urol 2002; 42:570-574
8. Wagner JR, Walther MM, Linehan WM, et al. Interleukin-2 based immunotherapy immunotherapy for metastatic renal cell carcinoma with the kidney in place. J Urol 1999; 162:43-45
9. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007; 356:115-124
10. Figlin RA, Hutson TE, Tomczak P, et al. Overall survival with sunitinib versus interferon (IFN)-alfa as first-line treatment of metastatic renal cell carcinoma (mRCC). J Clin Oncol 2008; 26(suppl):256s (Abstract 5024).
11. Flanigan RC, Salmon SE, Blumenstein BA, et al. Nephrectomy followed by interferon a-2b compared with interferon a-2bal one for metastatic renal-cell cancer. N Engl J Med 2001; 345:1655-1659
12. Mickisch GH, Garin A, van Poppel H, et al. Radical nephrectomy plus interferonabased immunotherapy compared with interferon a alone in metastatic renal-cell carcinoma: a randomised trial. Lancet 2001; 358:966-970
13. Flanigan RC, Mickisch G, Sylvester R, et al. Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. J Urol 2004; 171:1071-1076
14. Wood CG. Multimodal approaches in the management of locally advanced and metastatic renal cell carcinoma: combining surgery and systemic therapies to improve patient outcome. Clin Cancer Res 2007; 13:697s-702s.
15. Shuch B, Riggs SB, Larochelle JC, et al. Neoadjuvant targeted therapy and advanced kidney cancer: observations and implications for a new treatment paradigm. BJU Int 2008; Apr 10. [Epub ahead of print].
16. Van Der Veldt AA, Meijerink MR, Van Den Eertwegh AJ, et al. Sunitinib for treatment of advanced renal cell cancer: primary tumor response. Clin Cancer Res 2008; 14:2431-2436
17. Karakiewicz PI, Suardi N, Jeldres C, et al. Neoadjuvant sutent induction therapy may effectively down-stage renal cell carcinoma atrial thrombi. Eur Urol 2008; 53:845-848